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Abstract 
Patients with type 2 diabetes mellitus have a twofold increased risk of cardiovascular mortality compared with non-
diabetic individuals. There is a growing awareness that glycemic efficacy of anti-diabetic drugs does not necessarily 
translate to cardiovascular safety. Over the past few years, there has been a number of trials evaluating the cardio-
vascular effects of anti-diabetic drugs. In this review, we seek to examine the cardiovascular safety of these agents in 
major published trials. Metformin has with-stood the test of time and remains the initial drug of choice. The sulfonylu-
reas, despite being the oldest oral anti-diabetic drug, has been linked to adverse cardiovascular events and are gradu-
ally being out-classed by the various other second-line agents. The glitazones are contraindicated in heart failure. The 
incretin-based drugs have been at the fore-front of this era of cardiovascular safety trials and their performances have 
been reassuring, whereas the meglitinides and the alpha-glucosidase inhibitors still lack cardiovascular outcomes 
data. The sodium glucose cotransporter-2 inhibitors are an exciting new addition that has demonstrated a potential 
for cardiovascular benefit. Many of the currently available oral anti-diabetic agents have clinically relevant cardiovas-
cular effects. The optimal approach to the reduction of cardiovascular risk in diabetic patients should focus on aggres-
sive management of the standard cardiovascular risk factors rather than purely on intensive glycemic control.
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Background
Cardiovascular disease remains the leading cause of mor-
bidity and mortality in type 2 diabetes mellitus (T2DM). 
Despite a decline in the rate of cardiovascular mortal-
ity over time, men and women with diabetes mellitus 
remain at twofold increased risk [1]. However, in patients 
with long-standing T2DM, glucose lowering does not 
necessarily reduce adverse cardiovascular outcomes, as 
demonstrated by several large-scale randomized studies 
[2–4]. In fact, the action to control cardiovascular risk in 
diabetes (ACCORD) trial was terminated early due to a 
22% excess in cardiovascular mortality in the intensive 
glycemic control group [2]. Although the United King-
dom Prospective Diabetes Study (UKPDS) showed that 
glucose lowering reduced macrovascular complications 
in patients with newly diagnosed T2DM, this was only 
observed after median follow-up period of more than 
15 years [5].
In 2007, the highly publicized controversy surround-
ing the cardiovascular safety of rosiglitazone reinforced a 
growing awareness that glycemic efficacy is no longer the 
sole determinant of anti-diabetic drug pre-approval trials 
[6]. This led to a major change in United States Food and 
Drug Administration (FDA) policy in 2008, resulting in 
trials involving newer anti-diabetic drugs to emphasize 
cardiovascular safety [6].
The increasing prevalence of T2DM worldwide will 
likely be paralleled by a rise in prevalence of cardiovas-
cular disease. With the numerous anti-diabetic drugs 
available, there is a pressing need to clearly define their 
potential cardiovascular effects. Here, we review the 
contemporary literature examining the cardiovascular 
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Biguanides
Metformin
Metformin, along with the sulfonylureas, is one of two oral 
anti-diabetic drug groups listed on the World Health Organ-
ization Model Lists of Essential Medicines [7]. It inhibits 
hepatic gluconeogenesis and increases insulin-mediated 
glucose uptake in peripheral tissues [8]. Metformin reduces 
mean glycated hemoglobin (HbA1c) by approximately 1.5% 
compared to placebo [9], and promotes weight loss of up 
to 2.5 kg, sustainable over 10 years [10]. Long term therapy 
with metformin has also been shown to beneficially alter the 
lipid profile, reducing serum triglyceride and plasma total 
cholesterol levels and slightly increasing serum high-den-
sity-lipoprotein cholesterol levels [11]. Metformin may also 
have vascular protective effects through increased angio-
genesis by improving the angiogenic potential of CD34+ 
cells [12]. Furthermore, the potential beneficial actions of 
metformin on endothelial function have also been reported. 
For instance, metformin improved circulating endothelial 
progenitor cells in diabetic patients [13], as well as bone 
marrow endothelial progenitor cell functions in streptozo-
tocin-induced diabetic mice [14].
Cardiovascular safety
The UKPDS showed that metformin monotherapy in 
obese newly diagnosed T2DM patients was associated with 
a 32% reduction in the aggregate diabetes-related end-
point, including sudden death and myocardial infarction 
(MI) (p = 0.011), and 36% reduction in all-cause mortality 
(p = 0.011) [15]. This benefit was sustainable, with persis-
tent risk reductions observed in the metformin group for 
any diabetes-related endpoint (21%, p =  0.01), MI (33%, 
p = 0.005) and all-cause mortality (27%, p = 0.002), dur-
ing 10 years of post-trial follow-up of the UKPDS survivor 
cohort [5]. A meta-analysis of 35 randomized trials showed 
that metformin reduced adverse cardiovascular events 
(MI, stroke, peripheral artery disease and cardiovascular 
death) versus placebo/no therapy (MH-OR 0.79, 95% CI 
0.64–0.98, p = 0.031), but not against active-comparators 
(MH-OR 1.03, 95% CI 0.72–1.77, p =  0.89) [16]. A non-
significant trend towards reduced all-cause mortality was 
also noted with metformin monotherapy (MH-OR 0.801, 
95% CI 0.625–1.024, p = 0.076) [16]. This benefit may be 
especially pronounced in obese patients, with a systematic 
review of 29 trials reporting a reduction in all-cause mor-
tality with metformin in this population when compared 
with chlorpropamide, glyburide and insulin [17].
Metformin is not contraindicated in heart failure, 
although there has been concerns regarding its safety in 
this setting due to reports of increased incidence of lactic 
acidosis [18]. A systematic review of 9 cohort studies found 
no increased risk for morbidity and mortality with met-
formin use across various subgroups of patients with heart 
failure, including those with reduced left ventricular ejec-
tion fraction or concomitant chronic kidney disease [19].
Metformin use is restricted in the setting of iodinated 
contrast-enhanced procedures again due to a presumed 
association with lactic acidosis. However, an analysis of 
the Prevention of Restenosis with Tranilast and its Out-
comes (PRESTO) trial showed that diabetic patients 
undergoing coronary angioplasty who were treated 
with metformin had fewer rates of death (OR 0.39, 
95% CI 0.19–0.77, p = 0.007) and MI (OR 0.31, 95% CI 
0.15–0.66, p  =  0.002) compared to other anti-diabetic 
therapies [20]. Due to paucity of randomized evidence, 
guidelines vary substantially on their recommendations 
regarding the timing of discontinuation of metformin 
prior to contrast exposure [21, 22].
Summary
Metformin has an excellent cardiovascular safety profile, 
even with long-term use. Given its low cost, efficacy and 
proven safety record, guidelines recommend metformin 
as the first-line drug therapy of choice for T2DM [23, 
24]. Lactic acidosis is a rare but potentially fatal adverse 
effect. However, with an average estimated incidence of 
less than 0.03 per 1000 patient-years, this risk is minimal, 




The sulfonylureas are the oldest and most widely pre-
scribed oral anti-diabetic agents [25]. They bind to 
receptors on adenosine triphosphate-sensitive potas-
sium channels (KATP) in the pancreatic β-cells, causing 
depolarization of the cell membrane and subsequent 
calcium-mediated exocytosis of insulin-containing secre-
tory granules [26]. First-generation sulfonylureas such 
as tolbutamide and chlorpropamide are no longer used 
due to high incidence of adverse reactions [25]. Second-
generation agents include glipizide, glibenclamide (also 
known as glyburide in United States) and gliclazide. Sul-
fonylurea monotherapy reduces HbA1c by 1–2% [27], 
but weight gain is almost inevitable [25]. In the UKPDS, 
patients randomized to sulfonylureas gained a mean of 
5.3 kg over 6 years [28]. Glimepiride, a third-generation 
agent, has at least therapeutic equivalence to the second-
generation agents, but is less associated with both weight 
gain and hypoglycemia [29], and may have lesser unde-
sirable effects on myocardial preconditioning due to its 
selectivity to pancreatic KATP [30].
Cardiovascular safety
The University Group Diabetes Study (UGDS) first 
reported that T2DM patients randomized to tolbutamide 
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had increased cardiovascular mortality compared with 
placebo or insulin [31]. Several subsequent observa-
tional studies supported an association between sul-
fonylurea use and increased cardiovascular mortality 
[32–34]. Recent meta-analyses reported inconsistent 
findings. A review of 115 randomized trials found a 22% 
increased risk of all-cause mortality with sulfonylurea 
therapy compared with placebo or other anti-diabetic 
drugs (pooled-OR 1.22, 95% CI 1.01–1.49), although the 
overall incidence of major adverse cardiovascular events 
(MACE) appeared to be unaffected [35]. In contrast, a 
Cochrane review of 72 randomized trials reported no 
significant association between sulfonylureas and mortal-
ity compared with metformin monotherapy (pooled RR 
1.47, 95% CI 0.54–4.01) [27], despite the possible protec-
tive effects of metformin. Interference with protection 
from ischemic preconditioning due to blockade of mito-
chondrial KATP may contribute to the observed associa-
tion between sulfonylureas and cardiovascular mortality, 
although glibenclamide pre-treatment did not abrogate 
the protective effect of glucagon-like peptide-1 (GLP-1) 
in human models of non-lethal myocardial ischemia [36].
The impact of sulfonylureas on cardiovascular out-
comes may not be a class effect. There is evidence that 
whilst first-generation sulfonylureas were associated with 
increased cardiovascular mortality compared to placebo 
(RR 2.63, 95% CI 1.32–5.22, p = 0.006), no difference was 
found for second-generation agents [27]. A review of 18 
randomized trials showed that gliclazide was associated 
with a lower risk of all-cause (RR 0·65, 95% CI 0·53–0·79) 
and cardiovascular-related mortality (RR 0·60, 95% CI 
0·45–0·84) compared with glibenclamide [37], suggesting 
a possible benefit specific for gliclazide.
Summary
The newer sulfonylureas (gliclazide and glimepiride) may 
have a more favorable cardiovascular effect profile than 
older agents and should be the preferred agents in this 
class. Overall, due to their low cost and short-term glyce-
mic efficacy, the sulfonylureas are still strongly endorsed 
as second-line agents by international guidelines [23, 24].
Meglitinides
The meglitinides have similar action to sulfonylureas 
but are pharmacologically distinct and bind to different 
receptors on pancreatic KATP channels [38]. Currently 
available meglitinides include repaglinide and nategli-
nide. They exert similar but milder clinical effects com-
pared to sulfonylureas [39]. A Cochrane review of 15 
randomized trials showed that repaglinide was more effi-
cacious in HbA1c reduction than nateglinide (0.1–2.1% 
for repaglinide, 0.2–0.6% for nateglinide). These agents 
also cause weigh gains of up to 3 kg in 3 months [40].
Cardiovascular safety
There are currently no long-term studies of meglitinides 
to assess cardiovascular outcomes or mortality in T2DM, 
although the Nateglinide and Valsartan in Impaired Glu-
cose Tolerance Outcomes Research (NAVIGATOR) study 
may provide some insight. This was a large 2 × 2 facto-
rial randomized trial of nateglinide versus placebo, and 
valsartan versus placebo in 9306 patients with impaired 
glucose tolerance and cardiovascular disease or risk fac-
tors. After a median follow up of 5  years, there was no 
difference between nateglinide and placebo with respect 
to the core composite cardiovascular outcome of cardio-
vascular death, MI, stroke or heart failure hospitalization 
(7.9 vs 8.3%, HR 0.94, 95% CI 0.82–1.09, p = 0.43), or the 
extended composite cardiovascular outcome, including 
arterial revascularization and hospitalization for unsta-
ble angina (14.2 vs 15.2%, HR 0.93; 95% CI 0.83–1.03, 
p  =  0.16) [41]. A Danish nation-wide registry-based 
observational analysis showed that mortality and cardio-
vascular risk associated with the use of repaglinide, and 
gliclazide, was similar to metformin [42].
Summary
Meglitinides are associated with less hypoglycemia and 
weight gain compared with sulfonylureas [43]. However, 
due to the paucity of cardiovascular outcomes data, these 
agents should be reserved in favor of other anti-diabetic 
drugs.
Thiazolidinediones
The thiazolidinediones (TZDs), also known as glitazones, 
are a class of potent insulin-sensitizers which act by regu-
lating gene expression through selective ligand-binding 
of the nuclear transcription factor peroxisome-prolifer-
ator–activated receptor ɣ (PPARɣ) [44]. Rosiglitazone 
and pioglitazone are the currently approved agents in this 
class. The TZDs lowers HbA1c by 1–1.5% on average in 
placebo controlled studies, with low risk of hypoglyce-
mia [44]. An increase in body weight of 2–3 kg for every 
1% decrease in HbA1c is expected [44]. However, this 
weight gain is partly due to a redistribution of visceral fat 
to subcutaneous adipose tissue, and therefore may not 
be entirely undesirable [44]. Pioglitazone compared with 
rosiglitazone is associated with significant improvements 
in triglyceride and cholesterol profiles [45].
Cardiovascular safety
In a meta-analysis of 42 randomized trials, many of 
which were unpublished clinical trial registry data, rosigl-
itazone was associated with a significant increase in the 
risk of MI (OR 1.43, 95% CI 1.03–1.98, p = 0.03) and a 
non-significant trend for increased cardiovascular mor-
tality (OR 1.64, 95% CI 0.98–2.74, p  =  0.06) [46]. This 
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highly-publicized study resulted in a boxed warning of 
myocardial ischemia for rosiglitazone in 2007 [6]. In 
response, an interim analysis of the Rosiglitazone Evalu-
ated for Cardiac Outcomes and Regulation of Glycemia 
in Diabetes (RECORD) trial was published. This trial 
randomized 4447 T2DM patients to rosiglitazone plus 
either metformin or sulfonylurea or an active control 
(metformin plus sulfonylurea). No elevated risk for MI or 
death in the rosiglitazone group was noted at 3.75 years 
follow-up [47]. The final analysis showed that after a 
mean follow up of 5.5 years, rosiglitazone was non-infe-
rior to a combination of metformin and sulfonylurea 
with regards to the primary endpoint of cardiovascular 
hospitalization or cardiovascular death (HR 0·99, 95% CI 
0·85–1·16), but its effect on MI was inconclusive due to 
small number of events (HR 1·14, 95% CI 0·80–1·63) [48].
Pioglitazone was compared with placebo in the Pro-
spective Pioglitazone Clinical Trial in Macrovascular 
Events (PROACTIVE) study, which randomized 5238 
T2DM patients at high risk for macrovascular complica-
tions. The trial was terminated prematurely after an aver-
age follow up of 34.5 months due to significant reduction 
in the main secondary composite endpoint of all-cause 
mortality, non-fatal MI, and stroke in the pioglitazone 
group (HR 0·84, 95% CI 0·72–0·98, p  =  0·027). Piogl-
itazone also non-significantly reduced the composite 
primary endpoint of all-cause mortality and various car-
diovascular outcomes, including MI, stroke, and vascular 
interventions (HR 0·90, 95% CI 0·80–1·02, p  =  0·095) 
[49]. A meta-analysis of 19 randomized trials also showed 
a lower risk of death, MI or stroke with pioglitazone ther-
apy compared to placebo or active comparator (4.4% v 
5.7%, HR 0.82, 95% CI 0.72–0.94, p = 0.005) [50].
TZD use has consistently been associated with 
increased risk of heart failure, as shown in a meta-anal-
ysis of 29 placebo-controlled trials (5.3 vs 3.7%, OR 1.59, 
95% CI 1.34–1.89, p < 0.00001) [51]. In RECORD, rosigli-
tazone was associated with increased risk of fatal and 
non-fatal heart failure (HR 2.10, 95% CI 1.35–3.27) [48]. 
Similar findings were noted for pioglitazone in PROAC-
TIVE (HR 1.43, 95% CI 1.13–1.81) [49]. The Diabetes 
Reduction Assessment with Ramipril and Rosiglitazone 
Medication (DREAM) trial also showed that rosiglita-
zone therapy led to an increase in non-fatal heart failure 
in patients with impaired glucose tolerance (HR 7·03, 
95% CI 1.6–30.9, p = 0.01) [52].
Summary
Current data suggests increased caution with rosiglita-
zone use. In contrast, pioglitazone may confer cardio-
vascular benefits. There is no doubt however that both 
agents should be avoided in patients with or at risk for 
heart failure, and this is reflected in the latest European 
heart failure guidelines as a class IIIA recommendation 
[53]. Moreover, adverse side effects and relatively high 
drug costs limit the widespread use of TZDs as mono-
therapy, and they are more appropriately considered 
complementary to other oral anti-diabetic drugs. To 
receive maximum benefits, patients should have repeated 




The incretins, namely glucose-dependent insulinotropic 
peptide (GIP) and GLP-1, are insulinotropic gut hor-
mones that modulate the insulin secretory response to 
food intake in a glucose-dependent manner. They are 
rapidly degraded by circulating enzymes called dipep-
tidyl peptidase-4 (DPP-4) [55]. There are currently 4 
FDA-approved DPP-4 inhibitors: sitagliptin, saxagliptin, 
linagliptin and alogliptin. Vildagliptin is not available in 
United States. A meta-analysis reported 0.74% HbA1c 
reduction when treatment with sitagliptin and vilda-
gliptin was compared to placebo [56], and this glycemic 
efficacy appears to be equivalent across the class [57]. 
The DPP-4 inhibitors, otherwise known as the gliptins, 
are generally considered to have a neutral effect on 
weight [58]. It has been suggested that the modulation of 
endothelial progenitor cells, inflammatory pathways and 
ischemic response are the major cardiovascular targets of 
gliptins [59].
Cardiovascular safety
The Saxagliptin Assessment of Vascular Outcomes 
Recorded in Patients with Diabetes Mellitus—Throm-
bolysis in Myocardial Infarction (SAVOR-TIMI 53) trial 
randomized 16,492 patients with T2DM and either a his-
tory of cardiovascular disease or multiple vascular risk 
factors to receive saxagliptin or placebo on top of con-
ventional therapy. After a median follow-up of 2.1 years, 
there was no difference in the primary composite end-
point of cardiovascular death, non-fatal MI, or non-fatal 
ischemic stroke between groups (7.3 vs 7.2%, HR 1.00, 
95% CI 0.89–1.12, p = 0.99 for superiority, p < 0.001 for 
non-inferiority). However, in the pre-specified second-
ary end-points analysis, heart failure hospitalization was 
more common in the saxagliptin group (3·5 vs 2·8%, HR 
1·27, 95% CI 1·07–1·51, p  =  0·007) [60], although this 
increased risk subsided by 10–11 months after randomi-
zation [61].
In the Examination of Cardiovascular Outcomes with 
Alogliptin versus Standard of Care (EXAMINE) trial, 
which randomized 5380 patients with T2DM and a 
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recent acute coronary syndrome in the last 15–90 days, 
alogliptin was non-inferior to placebo with regards to 
the combined primary outcome of cardiovascular death, 
non-fatal MI or non-fatal stroke after a median follow up 
of 18 months (11.3 vs 11.8%, HR 0.96, upper boundary of 
one sided repeated CI 1.16; p < 0.001 for non-inferiority) 
[62]. A post hoc analysis showed that alogliptin had no 
effect on heart failure outcomes, including a composite 
of cardiovascular death and heart failure hospitalization 
(HR 1.00, 95% CI 0.82–1.21) [63].
Similarly, in the trial to evaluate cardiovascular out-
comes after treatment with sitagliptin (TECOS) study, 
which randomized 14,671 patients with T2DM, sitag-
liptin was non-inferior to placebo for the primary com-
posite outcome of cardiovascular death, non-fatal MI, 
non-fatal stroke, or hospitalization for unstable angina 
(HR 0.98, 95% CI 0.88–1.09, p < 0.001), with no difference 
in hospitalization rates for heart failure (HR 1.00, 95% CI 
0.83–1.20, p = 0.98) [64]. Sitgaliptin has also been shown 
to reduce blood pressure and improve albuminuria in a 
prospective study of Japanese patients with T2DM [65]. 
In addition, long-term use of sitagliptin up to 2 years did 
not adversely alter endothelial function in patients with 
T2DM [66].
The cardiovascular safety profile of linagliptin was 
investigated in a large patient-level pooled safety analysis 
of 19 clinical trials, which concluded that linagliptin was 
not associated with increased cardiovascular risk versus 
pooled active comparators or placebo in patients with 
T2DM, irrespective of background therapy [67].
Mostly driven by the results of the large SAVOR trial, 
a meta-analysis concluded that there was a slightly 
increased risk of hospitalization for heart failure in gliptin 
users compared with placebo (3.4 vs 3.0%, OR 1.13, 95% 
CI 1.00–1.26) [68]. However, the Canadian Network for 
Observational Drug Effect Studies (CNODES) retrospec-
tively analyzed administrative electronic health records 
of nearly 1.5 million patients and concluded that DPP-4 
inhibitors did not increase the rate of heart failure hos-
pitalization compared with oral anti-diabetic drug com-
binations among patients with (13.8 vs 11.6%, HR 0.87, 
95% CI, 0.63–1.21) or without a history of heart failure 
(9.6 vs 8.9%, HR 0.84, 95% CI 0.69–1.02) [69]. Another 
large scale cohort study analyzed an FDA database cover-
ing 358 million person-years of observation, also found 
no increased risk of heart failure hospitalizations in users 
of saxagliptin or sitagliptin compared with other selected 
anti-diabetic agents [70]. Furthermore, patients treated 
with gliptins in a comprehensive national cohort of dia-
betic patients in Taiwan had lower risks of cardiovascular 
disease, including heart failure, compared to non-gliptin 
users, except for metformin [71].
Summary
The DPP-4 inhibitors are safe in terms of hard cardio-
vascular endpoints, but their effect on the risk of heart 
failure remains uncertain. The clinical significance of the 
finding of an early increased hospitalization for heart 
failure with saxagliptin in the SAVOR study is unclear, 
although it is unlikely to be a class effect. The FDA safety 
review recommends considering discontinuation of spe-
cifically saxagliptin or alogliptin in patients who develops 
heart failure [72].
Glucagon‑like peptide‑1 agonists
The GLP-1 agonists are parenterally administered drugs 
that directly activate the GLP-1 receptor and are highly 
resistant to degradation by DPP-4. Currently available 
agents include: exenatide, liraglutide, albiglutide, lixi-
senatide, and dulaglutide. All are FDA-approved with the 
exception of lixisenatide, which is approved in Europe. 
GLP-1 agonists, when compared to placebo, reduced 
HbA1c by about 1% and resulted in 1.5–2.5  kg weight 
loss over 30  weeks [73]. In addition, treatment with 
GLP-1 agonists have been shown to further favorably 
alter the metabolic profile through modest reductions in 
low-density-lipoprotein cholesterol, total cholesterol and 
triglycerides [74], as well as reductions in systolic blood 
pressure (weighted mean difference −2.22  mmHg; 95% 
CI −2.97 to −1.47), although this may be accompanied 
by a compensatory increase in heart rate [75].
Cardiovascular safety
The cardioprotective effects of GLP-1 agonists have been 
well documented in pre-clinical studies. Indeed, experi-
mental models of ischemia and reperfusion have shown 
improved post-ischemic myocardial contractile dysfunc-
tion and reduced infarct size with constant infusions of 
GLP-1 [76]. In the clinical setting, similar positive effects 
have been observed to various degrees in pilot studies, 
and the mechanism was thought to be related to reduced 
apoptosis and nuclear oxidative stress and improvement 
in myocardial glucose metabolism [77].
The Evaluation of Lixisenatide in Acute Coronary 
Syndrome (ELIXA) trial randomized 6068 patients 
with T2DM and an acute coronary event within the 
last 180 days to receive lixisenatide or placebo on top of 
standard of care. After a median follow-up of 25 months, 
there was no difference in the primary composite end-
point of cardiovascular death, non-fatal MI, non-fatal 
stroke, or hospitalization for unstable angina between 
groups (13.4 vs 13.2%, HR 1.02, 95% CI 0.89–1.17, 
p  =  0.81 for superiority, p  <  0.001 for non-inferiority), 
and no difference in heart failure hospitalizations (4.0 vs 
4.2%, HR 0.96, 95% CI 0.75–1.23) [78].
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In the Liraglutide Effect And Action In Diabetes: Evalu-
ation Of Cardiovascular Outcome Results (LEADER) 
trial, which randomized 9340 T2DM patients with high 
cardiovascular risk, liraglutide reduced the primary com-
posite endpoint of cardiovascular death, non-fatal MI 
or non-fatal stroke compared to placebo after a median 
follow-up of 3.8 years (13 vs 14.9%, HR 0.8, 95% CI 0.78–
0.97, p < 0.001 for non-inferiority; p = 0.01 for superior-
ity). All-cause mortality was also reduced with liraglutide 
(8.2 vs 9.6%, HR 0.85, 95% CI 0.74–0.97, p = 0.02). The 
placebo group was more likely to receive added insulin 
or sulfonylureas, and consequently had a higher inci-
dence of severe hypoglycemia (3.3 vs 2.4%, p = 0.02) [79]. 
In another study of 41 newly diagnosed T2DM patients 
with stable coronary artery disease, although 12  weeks 
of liraglutide treatment, when compared to placebo, did 
not improve left ventricular ejection fraction, there was 
no increased risk of hospitalization for heart failure [80].
Although not currently FDA-approved, semaglutide, a 
once-weekly GLP-1 agonist, was non-inferior to placebo 
after 26  months follow-up among 3297 patients with 
T2DM in the Trial to Evaluate Cardiovascular and Other 
Long-term Outcomes with Semaglutide in Subjects with 
Type 2 Diabetes (SUSTAIN-6) with regards to the pri-
mary composite endpoint of cardiovascular death, non-
fatal MI and non-fatal stroke (HR 0.74, 95% CI 0.58–0.95, 
p < 0.001 for non- inferiority) [81]. Notably, majority of 
the trial patients had established cardiovascular dis-
ease, stage 3 or higher chronic kidney disease, or both at 
baseline.
Despite the lack of definitive randomized data, dula-
glutide, another once-weekly long-acting GLP-1 agonist, 
was not associated with an increased risk of MACE ver-
sus comparator therapy in a meta-analysis of phase 2 and 
phase 3 trials [82].
The retrospective CNODES study also showed that 
GLP-1 agonists did not increase heart failure hospitali-
zation among patients with (0.5 vs 0.7%, HR 0.75, 95% 
CI, 0.22–2.51) or without a history of heart failure (1.0 
vs 0.9%, HR 0.95, 95% CI 0.83–1.10) [69]. In fact, GLP-1 
infusion has been associated with improvements in left 
ventricular function in heart failure in both pre-clinical 
and clinical settings [77].
Summary
The LEADER trial is encouraging, but the outcomes may 
be biased in favor of liraglutide due to the detrimental 
effects of added anti-diabetic drugs in the placebo group. 
More long-term studies of GLP-1 agonists to assess car-
diovascular outcomes as well as the durability of weight 
loss are needed.
Sodium glucose cotransporter‑2 inhibitors
The sodium glucose cotransporter-2 (SGLT-2) is 
expressed in the proximal tubule and mediates reabsorp-
tion of up to 98% of urinary glucose [83]. Inhibition of 
SGLT-2 lowers blood glucose by promoting renal glucose 
excretion, which is independent of β-cell function and 
thus carries a low risk for hypoglycemia [84]. Currently, 
3 agents are approved in the United States and Europe: 
dapagliflozin, canagliflozin, and empagliflozin. SGLT-2 
inhibitors reduce HbA1c by 0.5–0.7% compared with pla-
cebo [85, 86], and promotes weight loss of 2–3  kg over 
12 weeks [83, 87]. It has a modest beneficial effect on the 
lipid profile through an increase in high-density-lipopro-
tein cholesterol and decrease in triglycerides [87]. In part 
due to the osmotic diuresis, SGLT-2 inhibitors also sig-
nificantly reduce both systolic (weighted mean difference 
−4.0  mmHg; 95% CI −4.4 to −3.5) and diastolic blood 
pressure (weighted mean difference −1.6 mmHg; 95% CI 
−1.9 to −1.3), without an increase in heart rate [88]. Fur-
thermore, empagliflozin has been shown in preclinical 
animal studies to prevent the development of endothelial 
dysfunction and reduce oxidative stress [89].
Cardiovascular safety
In the only cardiovascular outcomes trial of SGLT-2 
inhibitors reported to date, the randomized empagliflo-
zin cardiovascular outcome event trial in type 2 diabetes 
mellitus patients (EMPA-REG OUTCOME) trial of 7020 
patients with T2DM and established cardiovascular dis-
ease showed that after a median follow up of 3.1  years, 
empagliflozin was associated with a reduction in the pri-
mary composite endpoint of cardiovascular mortality, 
non-fatal MI, or non-fatal stroke compared with placebo 
(10.5 vs 12.1%, HR 0.86, 95% CI 0.74–0.99, p = 0.04 for 
superiority, NNT 62). A significant reduction in all-cause 
mortality (5.7 vs 8.3%, p  <  0.001, NNT 38) and cardio-
vascular mortality (3.7 vs 5.9%, p < 0.001, NNT 45) was 
also observed in the empagliflozin group. Further analy-
sis showed a 34% relative risk reduction of a composite 
of heart failure hospitalization or cardiovascular death 
with empagliflozin (5.7 vs 8.5%, HR 0.66, 95% CI 0.55–
0.79, p  <  0.001, NNT 35) [90]. Driven mainly by these 
results, a meta-analysis of data from regulatory submis-
sions and published trials suggested net protection of 
SGLT-2 inhibitors against cardiovascular outcomes and 
death [91]. Furthermore, empagliflozin has an excellent 
long term safety and tolerability profile. A study of empa-
gliflozin monotherapy for ≥76 weeks in T2DM patients 
showed a lower rate of drug discontinuation due to 
adverse events compared with placebo [92].
Page 7 of 12Xu and Rajaratnam  Cardiovasc Diabetol  (2017) 16:18 
A meta-analysis of phase 2 and phase 3 trials showed 
that dapagliflozin was not associated with an increased 
risk of MACE compared with placebo or comparator 
therapy in T2DM patients, and this observation was con-
sistent among patients with varying degrees of cardiovas-
cular risk [93].
Summary
The results from the EMPA-REG trial are very exciting. 
Although long-term clinical experience is still required, 
the SGLT-2 inhibitors is currently favored as the sec-
ond-line agent of choice in T2DM patients with a his-
tory of cardiovascular disease [94]. Additional data from 
planned and continuing studies of SGLT-2 inhibitors are 
eagerly awaited.
Alpha glucosidase inhibitors
The alpha glucosidase inhibitors (AGIs) lower blood glu-
cose through competitive blockade of intestinal alpha-
glucosidases, which convert complex carbohydrates into 
monosaccharides. This results in a modified intestinal 
absorption of carbohydrates and consequently a slower 
rise in post-prandial blood glucose [95]. Available agents 
include acarbose, miglitol and voglibose. A Cochrane 
meta-analysis reported a 0.8% HbA1c reduction and no 
clinically relevant effects on lipids or body weight when 
acarbose, the most widely prescribed AGI, was compared 
to placebo [96]. In addition, acarbose may also have ben-
eficial effects on endothelial function by obtunding post-
prandial glucotoxicity [95]. Miglitol, whilst having similar 
glycemic efficacy, may have a greater effect on reducing 
1 h post-prandial glucose levels than other AGIs [97]. A 
study of 47 Japanese patients with T2DM showed that 
switching from other AGIs to miglitol for 3 months sig-
nificantly improved glucose fluctuations and reduced 
serum concentrations of inflammatory cytokines [98]. 
Miglitol has also been shown to reduce waist circumfer-
ence, and in particular visceral fat, in patients with meta-
bolic syndrome [99].
Cardiovascular safety
There are no long-term studies examining the effect of 
AGIs on cardiovascular disease or mortality in T2DM. 
The Study to Prevent Non-insulin-dependent Diabe-
tes Mellitus (STOP-NIDDM) trial randomized 1429 
patients with impaired glucose tolerance and showed 
that after a mean follow-up of 3.3 years, acarbose treat-
ment was associated with a significant risk reduction 
in the development of diabetes (HR 0.75, 95% CI 0.63–
0.90, p = 0.0015) [100] and hypertension (HR 0.66, 95% 
CI 0.49–0.89, p  =  0.006) [101], compared to placebo. 
Although not initially powered to draw conclusions on 
cardiovascular outcomes, acarbose treatment was also 
associated with a reduction in the development of the 
composite outcome of cardiovascular events, which 
includes cardiovascular death, MI, stroke, heart failure, 
peripheral vascular disease and revascularization (HR 
0.51, 95% CI 0.28–0.95, p = 0.03) [101].
Summary
Long-term cardiovascular outcomes data is lacking for 
the AGIs in T2DM and therefore these cannot be recom-
mended over the other available agents. However, treat-
ment is associated with minimal adverse effects and low 
risk of hypoglycemia.
Conclusions
Due to a high prevalence of cardiovascular morbidity and 
mortality in T2DM, the optimal approach to the reduc-
tion of cardiovascular risk should focus on aggressive 
management of the standard cardiovascular risk factors 
rather than purely on intensive glycemic control. As can 
be seen from the various trials reviewed here, favora-
ble glycemic efficacy does not necessarily translate to 
favorable cardiovascular outcomes (Table  1). Clinicians 
must therefore make careful informed decisions based 
on the cardiovascular effects of the various anti-diabetic 
drugs when prescribing (Table 2). Based on current evi-
dence, metformin should remain the first-line drug of 
choice in T2DM, being the most extensively studied and 
demonstrating excellent cardiovascular safety even with 
long term use. Although evidence for the cardiovascular 
safety of sulfonylureas are inconsistent, the first-gener-
ation agents are probably associated with net harm and 
should be avoided. Newer generation sulfonylureas have 
a comparatively more favorable cardiovascular profile, 
but weight gain remains a concern. The meglitinides 
and AGIs lack cardiovascular safety data in T2DM and 
should therefore be reserved in favor of other second-line 
agents. Among the TZDs, rosiglitazone may be associ-
ated with an increased risk of MI, while pioglitazone may 
have beneficial cardiovascular effects. Both are however 
contraindicated in heart failure. The incretin-based drugs 
have been at the forefront of this era of cardiovascular 
safety trials and have been extensively studied. Current 
evidence suggests that the gliptins have neutral overall 
cardiovascular effect, but may increase risk of heart fail-
ure, particularly saxagliptin. Among the GLP-1 agonists, 
liraglutide may have beneficial effects on cardiovascular 
outcomes, but this requires further validation. Similarly, 
the SGLT-2 inhibitors have shown promising results with 
empagliflozin and may potentially confer cardiovascular 
benefits, although additional data is needed to substan-
tiate this. With results of several large ongoing rand-
omized trials expected in the coming years (Table 3), the 
body of evidence will continue to expand and help guide 
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clinicians in making the best decision in reducing the 
cardiovascular risk of their diabetic patients.
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Table 2 Suggested preference of pharmacotherapy in type 2 diabetes based on cardiovascular effects
TZDs thiazolidinediones, DPP-4 dipeptidyl peptidase-4, GLP-1 glucagon-like peptide-1, SGLT-2 sodium glucose cotransporter 2, AGIs alpha-glucosidase inhibitors
a Specifically saxagliptin and alogliptin; note that sitagliptin may be used
Acceptable Avoid No data
Established or at risk of heart failure
Metformin TZDs Meglitinides
Sulfonylureas DPP-4 inhibitorsa AGIs
SGLT-2 inhibitors
Established cardiovascular disease
Metformin 1st generation sulfonylureas Meglitinides




Table 3 Upcoming cardiovascular outcomes trials in type 2 diabetes
CV cardiovascular, MI myocardial infarction
Study Drug Comparator Primary endpoint Results
CANVAS Canagliflozin Placebo Major adverse cardiovascular events, including CV death, non-fatal MI, and non-
fatal stroke
2017
CARMELINA Linagliptin Placebo Composite endpoint: cardiovascular death, non-fatal myocardial infarction, non-
fatal stroke and hospitalization for unstable angina pectoris
2018
EXSCEL Exenatide once 
weekly
Placebo Composite endpoint: cardiovascular death, non-fatal MI, or non-fatal stroke 2018
REWIND Dulaglutide Placebo Composite endpoint: cardiovascular death, non-fatal MI, or non-fatal stroke 2018
DECLARE-TIMI 58 Dapagliflozin Placebo Composite endpoint: CV death, MI or ischemic stroke 2019
CAROLINA Linagliptin Glimepiride Composite endpoint: CV death, non-fatal MI (excluding silent MI), non-fatal stroke 
and hospitalisation for unstable angina pectoris
2019
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